Drug Delivery Deal Valuations
In recent years, Big Pharma has increasingly begun to regard drug delivery as an important part of the drug development process, rather than merely an issue of prolonging the marketplace life of aging products, particularly when it comes to the delivery of large molecules. Average deal valuations in drug delivery have jumped accordingly.
You may also be interested in...
Transdermal drug delivery has come a long way since the first patch for seasickness. In a drug delivery device industry on track to reach almost $23 billion by the year 2011 (according to "US Markets for Drug and Fluid Delivery Devices," published in October 2007 by Windhover Information's Medtech Insight division) the transdermal sector will grow at a faster rate than injection or inhalation drug delivery systems. Transdermal delivery technologies will grow at a compound annual rate of more than 11% over the next four years, building up to sales of $3.5 billion in the year 2011.
If President Donald Trump appoints, and the Senate approves, a new conservative justice for the Supreme Court to replace Ruth Bader Ginsburg, Affordable Care Act coverage could disappear. Two legal experts weigh in on this and other legal issues that could touch the medical device industry.
The Dutch start-up will use the funds to finalize product design for a neurostimulation platform targeting chronic migraines.